Davis M. Hahn

407 total citations
9 papers, 323 citations indexed

About

Davis M. Hahn is a scholar working on Oncology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Davis M. Hahn has authored 9 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Infectious Diseases and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Davis M. Hahn's work include Neutropenia and Cancer Infections (5 papers), Antimicrobial Resistance in Staphylococcus (3 papers) and Bacterial Identification and Susceptibility Testing (2 papers). Davis M. Hahn is often cited by papers focused on Neutropenia and Cancer Infections (5 papers), Antimicrobial Resistance in Staphylococcus (3 papers) and Bacterial Identification and Susceptibility Testing (2 papers). Davis M. Hahn collaborates with scholars based in United States. Davis M. Hahn's co-authors include Peter H. Wiernik, Clarence L. Fortner, Viola Mae Young, Stephen C. Schimpff, Harold C. Standiford, John F. Bender, Merrill J. Egorin, S. Ostrow, A Leroy and Joseph Aisner and has published in prestigious journals such as Cancer, The American Journal of Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Davis M. Hahn

9 papers receiving 249 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Davis M. Hahn United States	8	168	86	77	74	53	9	323
Harold Gaya United Kingdom	8	279 1.7×	51 0.6×	98 1.3×	175 2.4×	7 0.1×	13	368
A. Paul Vastola United States	8	70 0.4×	179 2.1×	55 0.7×	50 0.7×	12 0.2×	8	396
F. Wendt Germany	10	129 0.8×	23 0.3×	64 0.8×	31 0.4×	4 0.1×	33	335
Lobna Shalaby Egypt	10	130 0.8×	23 0.3×	93 1.2×	66 0.9×	12 0.2×	30	278
Carmina Martí Spain	7	39 0.2×	58 0.7×	128 1.7×	32 0.4×	12 0.2×	9	274
Rinzō Soejima Japan	12	40 0.2×	92 1.1×	135 1.8×	7 0.1×	25 0.5×	55	428
J.L. Pellegrin France	12	77 0.5×	22 0.3×	101 1.3×	19 0.3×	35 0.7×	27	463
Tanya O’Neal United States	9	86 0.5×	86 1.0×	76 1.0×	55 0.7×	8 0.2×	11	302
Masamichi Komiya Japan	10	32 0.2×	119 1.4×	46 0.6×	20 0.3×	38 0.7×	52	320
Yasutaka Nakamura Japan	12	36 0.2×	35 0.4×	64 0.8×	38 0.5×	15 0.3×	64	385

Countries citing papers authored by Davis M. Hahn

Since Specialization

Citations

This map shows the geographic impact of Davis M. Hahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davis M. Hahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davis M. Hahn more than expected).

Fields of papers citing papers by Davis M. Hahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davis M. Hahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davis M. Hahn. The network helps show where Davis M. Hahn may publish in the future.

Co-authorship network of co-authors of Davis M. Hahn

This figure shows the co-authorship network connecting the top 25 collaborators of Davis M. Hahn. A scholar is included among the top collaborators of Davis M. Hahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davis M. Hahn. Davis M. Hahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Ostrow, S., Merrill J. Egorin, Davis M. Hahn, et al.. (1981). High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.. PubMed. 65(1-2). 73–8. 66 indexed citations

Ostrow, S., Merrill J. Egorin, Davis M. Hahn, et al.. (1980). Cis-dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer. 46(8). 1715–1721. 28 indexed citations

Schimpff, Stephen C., Davis M. Hahn, Viola Mae Young, et al.. (1979). Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. The American Journal of Medicine. 66(4). 603–610. 77 indexed citations

Bender, John F., Clarence L. Fortner, Stephen C. Schimpff, et al.. (1979). Comparative auditory toxicity of aminoglycoside antibiotics in ieukopenic patients. American Journal of Health-System Pharmacy. 36(8). 1083–1087. 17 indexed citations

Schimpff, Stephen C., et al.. (1978). Comparison of basic infection prevention techniques, with standard room reverse isolation or with reverse isolation plus added air filtration. Leukemia Research. 2(3). 231–240. 23 indexed citations

Hahn, Davis M., et al.. (1978). Infection in Acute Leukemia Patients Receiving Oral Nonabsorbable Antibiotics. Antimicrobial Agents and Chemotherapy. 13(6). 958–964. 53 indexed citations

Hahn, Davis M., et al.. (1977). Amikacin and Cephalothin: Empiric Regimen for Granulocytopenic Cancer Patients. Antimicrobial Agents and Chemotherapy. 12(5). 618–624. 25 indexed citations

Hahn, Davis M., et al.. (1977). [The treatment of metastasizing hypernephroid (renal cell) carcinoma with medroxyprogesterone acetate (Clinovir) (author's transl].. PubMed. 119(34). 1089–92. 1 indexed citations

Schimpff, Stephen C., Sheldon H. Landesman, Davis M. Hahn, et al.. (1976). Ticarcillin in Combination with Cephalothin or Gentamicin as Empiric Antibiotic Therapy in Granulocytopenic Cancer Patients. Antimicrobial Agents and Chemotherapy. 10(5). 837–844. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact